StreetInsider.com News Articles

Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio

Thu, 16 Jul 2026 07:30:00 -0400

Initial Medical Cannabis SKUs, Including Rapid-Onset Capsules and Soft Chews, Planned for Q3 2026 Improving Patient Access with Accurately Dosed, Rapid-Onset and Non-Combustible Formats

TORONTO, July 16, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, today announced the introduction of its proprietary QUIX™-powered rapid-onset medical cannabis portfolio, with initial SKUs to be available across Canadian medical cannabis channels starting the third quarter of 2026 and additional SKUs planned for later in the year.

Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio

Thu, 16 Jul 2026 07:30:00 -0400

Initial Medical Cannabis SKUs, Including Rapid-Onset Capsules and Soft Chews, Planned for Q3 2026 Improving Patient Access with Accurately Dosed, Rapid-Onset and Non-Combustible Formats

Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio

Thu, 16 Jul 2026 07:30:00 -0400

Initial Medical Cannabis SKUs, Including Rapid-Onset Capsules and Soft Chews, Planned for Q3 2026 Improving Patient Access with Accurately Dosed, Rapid-Onset and Non-Combustible Formats

Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio

Thu, 16 Jul 2026 07:30:00 -0400

Initial Medical Cannabis SKUs, Including Rapid-Onset Capsules and Soft Chews, Planned for Q3 2026 Improving Patient Access with Accurately Dosed, Rapid-Onset and Non-Combustible Formats

Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio

Thu, 16 Jul 2026 07:30:00 -0400

Initial Medical Cannabis SKUs, Including Rapid-Onset Capsules and Soft Chews, Planned for Q3 2026 Improving Patient Access with Accurately Dosed, Rapid-Onset and Non-Combustible Formats

Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio

Thu, 16 Jul 2026 07:30:00 -0400

Initial Medical Cannabis SKUs, Including Rapid-Onset Capsules and Soft Chews, Planned for Q3 2026 Improving Patient Access with Accurately Dosed, Rapid-Onset and Non-Combustible Formats

Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio

Thu, 16 Jul 2026 07:30:00 -0400

Initial Medical Cannabis SKUs, Including Rapid-Onset Capsules and Soft Chews, Planned for Q3 2026 Improving Patient Access with Accurately Dosed, Rapid-Onset and Non-Combustible Formats

Avicanna Introduces QUIX™ Rapid-Onset Medical Cannabis Portfolio

Thu, 16 Jul 2026 07:30:00 -0400

Initial Medical Cannabis SKUs, Including Rapid-Onset Capsules and Soft Chews, Planned for Q3 2026 Improving Patient Access with Accurately Dosed, Rapid-Onset and Non-Combustible Formats

Avicanna names Nick Hilborn as permanent CFO

Tue, 30 Jun 2026 17:30:11 -0400

Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) has promoted Nick Hilborn, CPA, CA, to Chief Financial Officer, effective immediately, according to a press release from the Toronto-based biopharmaceutical company.

Hilborn had served as Interim CFO since September 2025 and previously held the role of Vice President of Finance at Avicanna since July 2024. Before joining the company, he held positions at Telus, EY, and PwC.

Avicanna names Nick Hilborn as permanent CFO

Tue, 30 Jun 2026 17:30:11 -0400

Avicanna names Nick Hilborn as permanent CFO

Tue, 30 Jun 2026 17:30:11 -0400

Avicanna names Nick Hilborn as permanent CFO

Tue, 30 Jun 2026 17:30:11 -0400

Avicanna Announces Promotion of Nick Hilborn CPA CA to Chief Financial Officer

Tue, 30 Jun 2026 17:30:00 -0400

TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce Mr. Nick Hilborn, CPA, CA has been promoted to the position of Chief Financial Officer (CFO) effective immediately. Mr. Hilborn served as the Interim CFO at the Company since September 2025, and previously held the role of Vice President of Finance since July 2024. Prior to joining the Company, Mr. Hilborn held roles at Telus, EY, and PwC.

About

Avicanna Announces Promotion of Nick Hilborn CPA CA to Chief Financial Officer

Tue, 30 Jun 2026 17:30:00 -0400

TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce Mr. Nick Hilborn, CPA, CA has been promoted to the position of Chief Financial Officer (CFO) effective immediately. Mr. Hilborn served as the Interim CFO at the Company since September 2025, and previously held the role of Vice President of Finance since July 2024. Prior to joining the Company, Mr. Hilborn held roles at Telus, EY, and PwC.

About

Avicanna Announces Promotion of Nick Hilborn CPA CA to Chief Financial Officer

Tue, 30 Jun 2026 17:30:00 -0400

TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce Mr. Nick Hilborn, CPA, CA has been promoted to the position of Chief Financial Officer (CFO) effective immediately. Mr. Hilborn served as the Interim CFO at the Company since September 2025, and previously held the role of Vice President of Finance since July 2024. Prior to joining the Company, Mr. Hilborn held roles at Telus, EY, and PwC.

About

Avicanna Announces Promotion of Nick Hilborn CPA CA to Chief Financial Officer

Tue, 30 Jun 2026 17:30:00 -0400

TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce Mr. Nick Hilborn, CPA, CA has been promoted to the position of Chief Financial Officer (CFO) effective immediately. Mr. Hilborn served as the Interim CFO at the Company since September 2025, and previously held the role of Vice President of Finance since July 2024. Prior to joining the Company, Mr. Hilborn held roles at Telus, EY, and PwC.

About

Avicanna Announces Promotion of Nick Hilborn CPA CA to Chief Financial Officer

Tue, 30 Jun 2026 17:30:00 -0400

TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce Mr. Nick Hilborn, CPA, CA has been promoted to the position of Chief Financial Officer (CFO) effective immediately. Mr. Hilborn served as the Interim CFO at the Company since September 2025, and previously held the role of Vice President of Finance since July 2024. Prior to joining the Company, Mr. Hilborn held roles at Telus, EY, and PwC.

About

Avicanna Announces Promotion of Nick Hilborn CPA CA to Chief Financial Officer

Tue, 30 Jun 2026 17:30:00 -0400

TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce Mr. Nick Hilborn, CPA, CA has been promoted to the position of Chief Financial Officer (CFO) effective immediately. Mr. Hilborn served as the Interim CFO at the Company since September 2025, and previously held the role of Vice President of Finance since July 2024. Prior to joining the Company, Mr. Hilborn held roles at Telus, EY, and PwC.

About

Avicanna Announces Promotion of Nick Hilborn CPA CA to Chief Financial Officer

Tue, 30 Jun 2026 17:30:00 -0400

TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce Mr. Nick Hilborn, CPA, CA has been promoted to the position of Chief Financial Officer (CFO) effective immediately. Mr. Hilborn served as the Interim CFO at the Company since September 2025, and previously held the role of Vice President of Finance since July 2024. Prior to joining the Company, Mr. Hilborn held roles at Telus, EY, and PwC.

About

Avicanna Announces Promotion of Nick Hilborn CPA CA to Chief Financial Officer

Tue, 30 Jun 2026 17:30:00 -0400

TORONTO, June 30, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce Mr. Nick Hilborn, CPA, CA has been promoted to the position of Chief Financial Officer (CFO) effective immediately. Mr. Hilborn served as the Interim CFO at the Company since September 2025, and previously held the role of Vice President of Finance since July 2024. Prior to joining the Company, Mr. Hilborn held roles at Telus, EY, and PwC.

About

Avicanna Reports Q1 2026 Financial Statements

Thu, 14 May 2026 07:30:00 -0400

Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion
Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce its financial results for Q1 2026, including the related financial statements and management’s discussion and analysis.

“The first quarter of 2026 reflects continued execution across Avicanna’s integrated commercial

Avicanna Reports Q1 2026 Financial Statements

Thu, 14 May 2026 07:30:00 -0400

Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion
Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce its financial results for Q1 2026, including the related financial statements and management’s discussion and analysis.

“The first quarter of 2026 reflects continued execution across Avicanna’s integrated commercial

Avicanna Reports Q1 2026 Financial Statements

Thu, 14 May 2026 07:30:00 -0400

Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion
Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce its financial results for Q1 2026, including the related financial statements and management’s discussion and analysis.

“The first quarter of 2026 reflects continued execution across Avicanna’s integrated commercial

Avicanna Reports Q1 2026 Financial Statements

Thu, 14 May 2026 07:30:00 -0400

Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion
Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce its financial results for Q1 2026, including the related financial statements and management’s discussion and analysis.

“The first quarter of 2026 reflects continued execution across Avicanna’s integrated commercial

Avicanna Reports Q1 2026 Financial Statements

Thu, 14 May 2026 07:30:00 -0400

Record revenue and gross profits driven by Canadian commercial growth and proprietary product expansion
Continued advancement of pharmaceutical pipeline, medical affairs initiatives and international platform

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products is pleased to announce its financial results for Q1 2026, including the related financial statements and management’s discussion and analysis.

“The first quarter of 2026 reflects continued execution across Avicanna’s integrated commercial